里程碑医药在华获批触发200万美元里程碑付款

投资观察09-03 23:00

9月3日（路透社）——Milestone Pharmaceuticals Inc.（股票代码：MIST）今日宣布，其用于治疗阵发性室上性心动过速（PSVT）的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局（NMPA）的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。

该公司进一步披露，NMPA的此次批准触发了云顶新耀（股票代码：01952）应向Milestone Pharmaceuticals支付的200万美元里程碑付款。根据双方的协议，云顶新耀持有依曲帕米鼻喷雾剂在大中华区的独家许可权。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1140066454?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-03 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140066454","market":"us","top_or_hot":-1,"title":"里程碑医药在华获批触发200万美元里程碑付款","media":"投资观察","content":"<p>9月3日（路透社）——Milestone Pharmaceuticals Inc.（股票代码：MIST）今日宣布，其用于治疗阵发性室上性心动过速（PSVT）的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局（NMPA）的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。</p>\n<p>该公司进一步披露，NMPA的此次批准触发了云顶新耀（股票代码：01952）应向Milestone Pharmaceuticals支付的200万美元里程碑付款。根据双方的协议，云顶新耀持有依曲帕米鼻喷雾剂在大中华区的独家许可权。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>里程碑医药在华获批触发200万美元里程碑付款</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n里程碑医药在华获批触发200万美元里程碑付款\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-03 23:00 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月3日（路透社）——Milestone Pharmaceuticals Inc.（股票代码：MIST）今日宣布，其用于治疗阵发性室上性心动过速（PSVT）的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局（NMPA）的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。\n该公司进一步披露，NMPA的此次批准触发了云顶新耀（股票代码：01952）应向Milestone ...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1140066454","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140066454","pubTimestamp":1788447612,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"9月3日（路透社）——Milestone Pharmaceuticals Inc.今日宣布，其用于治疗阵发性室上性心动过速的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。该公司进一步披露，NMPA的此次批准触发了云顶新耀应向Milestone Pharmaceuticals支付的200万美元里程碑付款。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK1583":"高瓴概念","01952":"云顶新耀","MIST":"Milestone Pharmaceuticals Inc.","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Milestone Pharma's approval in China triggers a $2 million milestone payment.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1,"MIST":1},"content_text":"9月3日（路透社）——Milestone Pharmaceuticals Inc.（股票代码：MIST）今日宣布，其用于治疗阵发性室上性心动过速（PSVT）的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局（NMPA）的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。\n该公司进一步披露，NMPA的此次批准触发了云顶新耀（股票代码：01952）应向Milestone Pharmaceuticals支付的200万美元里程碑付款。根据双方的协议，云顶新耀持有依曲帕米鼻喷雾剂在大中华区的独家许可权。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140066454","isCrawlerRequest":true}